MedDataX Logo

Peri-vascular Adipose Tissue Inflammation Evaluated Using Coronary CT Angiography

NCT ID: NCT04181749

Last Updated: 2023-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-11-18

Study Completion Date

2024-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The P-VECT Study proposes to test the use of CCTA-derived FAI measurements in a group of patients with coronary artery inflammation, who will receive routinely-used statin and aspirin treatment. The P-VECT Study is a pilot study that will provide the rationale and data for power calculations to enable design of pivotal trials of the clinical effectiveness of FAI.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this research we will study the ability of coronary CT angiography (CCTA)- derived Fat Attenuation Index (FAI) measurements to detect changes in coronary artery inflammation following treatment with atorvastatin and aspirin . CT scan images are used to evaluate the presence of atherosclerotic plaque in the wall of the coronary arteries. The new CCTA technique, FAI, detects and quantifies coronary artery inflammation by analysis of the characteristics of the adipose tissue (fat) around the wall of the artery - the peri-vascular adipose tissue (PVAT) This is a pilot study, involving patients undergoing a clinically indicated CCTA as part of their routine clinical care who are shown (on their scans) to have mild coronary artery plaques (\<50% luminal stenosis) with a high FAI value (\>70.1 HU). Patients will have 6 visits (one of which screening) with hospital attendance on 3 occasions for blood tests and drug supply. The pilot study will provide the rationale for power calculations from which further studies can be developed to evaluate the clinical effectiveness of FAI.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Risk Factor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Patients randomized to No treatment or Aspirin and Statin
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

No treatment

Patients will not be prescribed aspirin and statin

Group Type NO_INTERVENTION

No interventions assigned to this group

Aspirin and Atorvastatin

Patients prescribed aspirin and atorvastatin

Group Type ACTIVE_COMPARATOR

aspirin and atorvastatin

Intervention Type DRUG

Patients will be randomized and prescribed either no treatment or aspirin 75mg and Atorvastatin 40mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

aspirin and atorvastatin

Patients will be randomized and prescribed either no treatment or aspirin 75mg and Atorvastatin 40mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Participants must satisfy the following conditions:

1. Male or Female, aged 30 to 80 years,
2. CCTA scan showing mild coronary artery plaques (\<50% luminal stenosis) with a high FAI value (\>70.1 HU) within last 3 months.
3. No definite clinical indication for statin treatment (i.e. do not have either cholesterol \>6.5 mM, or cholesterol \>5.0 mM and QRISK score \>10%).
4. Clinical equipoise for statin and aspirin treatment, as determined by the local treating physician. In these patients, there is clinical equipoise because routine treatment with aspirin and statin is not mandated by current guidelines, but the presence of minor coronary artery plaques is frequently interpreted by clinicians as an indication for aspirin and statin treatment. Accordingly, some patients in this group typically receive aspirin and statin treatment, whereas others do not.
5. Willing and able (in the Investigators opinion) to comply with all study requirements.
6. Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of any incidental findings.
7. Able to understand both verbal or written English

\-

Exclusion Criteria

* The participant may not enter the study if ANY of the following are known to apply:

1. Previous documented history of coronary artery disease requiring treatment. This includes any of the following:

Acute myocardial infarction Unstable angina Coronary revascularization procedure Clinically significant coronary artery disease diagnosed by invasive or non-invasive testing.
2. Known diabetes mellitus
3. Definite clinical indication for statin treatment (i.e. has either cholesterol \>6.5 mM, or cholesterol \>5.0 mM and QRISK score \>10%).
4. Treatment with aspirin, statin or any prescribed lipid modification therapy in 6 weeks before baseline CCTA
5. Atrial fibrillation (paroxysmal or persistent)
6. History of New York Heart Association (NYHA) Class III or IV heart failure within the past 12 months of consent.
7. Autoimmune disease requiring immunosuppressive therapy or systemic corticosteroid therapy
8. Active treatment with any anti-inflammatory agents (e.g. NSAIDs, corticosteroids)
9. Active neoplasm requiring surgery, chemotherapy, or radiation within the prior 12 months (subjects with a history of malignancy who have undergone curative resection or otherwise not requiring treatment for at least 12 months prior to screening with no detectable recurrence are allowed)
10. Contraindication for aspirin and/or statin therapy
11. Severe Chronic kidney disease (estimated glomerular filtration rate \< 30 mL/min/1.73 m² and/or serum creatinine \> 2.5 mg/dL or 220 µmol/l).
12. Hepatic dysfunction (aspartate aminotransferase \[AST\] or alanine aminotransferase \[ALT\] \> 3 × the upper limit of normal \[ULN\] measured on local labs in last 6 months)
13. Any clinically significant abnormality identified at the time of screening that, in the opinion of the Investigator, would preclude safe completion of the study.
14. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
15. Participants who have participated in another research study involving a treatment intervention or an investigational product, in the past 12 weeks.
16. Patients unable to understand verbal or written English.
17. Contraindication to contract dye for CCTA.
18. Pregnancy
Minimum Eligible Age

30 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Oxford

OTHER

Sponsor Role collaborator

British Heart Foundation

OTHER

Sponsor Role collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

Sponsor Role collaborator

University of Leicester

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David Adlam, Dr.

Role: PRINCIPAL_INVESTIGATOR

University Hospitals of Leicester and University of Leicester

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospitals of Leicester

Leicester, , United Kingdom

Site Status RECRUITING

Royal Brompton Hospitals Trust

London, , United Kingdom

Site Status RECRUITING

John Radcliffe Hospital

Oxford, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Alexander

Role: CONTACT

Phone: 0116 2583839

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Donna Alexander

Role: primary

Ciara Mahon

Role: primary

Vicky Toghill

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0719

Identifier Type: -

Identifier Source: org_study_id